Revenue: As of FY2025 Q1, the actual value is USD 163.55 K.EPS: As of FY2025 Q1, the actual value is USD -1.56, missing the estimate of USD -1.315.EBIT: As of FY2025 Q1, the actual value is USD -1.911 M, beating the estimate of USD -1.918 M.<h3>Segment Revenue</h3><ul><li>Product Revenues – net of Discounts and Rebates: $163,552 for the three months ended March 31, 2025, compared to $105,674 for the same period in 2024, representing a 54.77% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $90,280 for the three months ended March 31, 2025, compared to $40,237 for the same period in 2024, representing a 124.37% increase.</li><li>Loss from Operations: - $1,910,875 for the three months ended March 31, 2025, compared to - $1,342,448 for the same period in 2024.</li><li>Net (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc.: - $1,876,549 for the three months ended March 31, 2025, compared to $430,470 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $1,597,366 for the three months ended March 31, 2025, compared to - $1,140,438 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $1,702,518 for the three months ended March 31, 2025, compared to - $9,814 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $1,696,899 for the three months ended March 31, 2025, compared to $1,903,291 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Research Revenues: $92,731 for the three months ended March 31, 2025, compared to $29,631 for the same period in 2024, representing a 212.95% increase.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to increase sales of Arakoda, conduct clinical trials to expand the number of patients who can use Tafenoquine for new indications, and reposition small molecule therapeutics for new indications.</li><li>Non-Core Business: The company has suspended its Phase IIB study for COVID-19 and is focusing on the commercialization of Arakoda for malaria and further evaluation of Tafenoquine for babesiosis and other diseases.</li><li>Priority: The company aims to achieve profitability and grow shareholder value by increasing sales of Arakoda and expanding its clinical trials for new indications.</li></ul>

60 Degrees Pharmaceuticals | 10-Q: FY2025 Q1 Revenue: USD 163.55 K